Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease (Q46987576)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2006

Language	Label	Description	Also known as
English	Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease	scientific article published in June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

Parkinson's disease

1 reference

based on heuristic

inferred from title

Tom H. Johnston

2

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

4

object named as

Susan H Fox

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

Jonathan M. Brotchie

5

object named as

Jonathan M Brotchie

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

Naomi P. Visanji

3

object named as

Naomi P Visanji

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

Jordi Gomez-Ramirez

1

object named as

Jordi Gomez-Ramirez

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

21

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

6

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

839-846

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

Pathophysiology of bradykinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Levodopa-induced dyskinesia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Long-lasting dyskinesia induced by levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Treatment of Parkinsonism With Levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H(3) receptors depress synaptic transmission in the corticostriatal pathway

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H3-receptor activation inhibits dopamine synthesis in rat striatum

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTP gamma[S] binding to pertussis toxin

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Presynaptic H3 autoreceptors modulate histamine synthesis through cAMP pathway.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

H3 autoreceptors modulate histamine synthesis through calcium/calmodulin- and cAMP-dependent protein kinase pathways.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Highly potent and selective ligands for histamine H3-receptors

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.20828

21 January 2018

Identifiers

10.1002/MDS.20828

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16532454

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46987576&oldid=2140954793"